Genocea Biosciences Inc (GNCAQ)
0.00
USD |
OTCM |
Apr 26, 16:00
Price Chart
Key Stats
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 100.00% |
Profile
| Genocea Biosciences Inc is a US-based biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs. Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns a pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines. |
| URL | https://www.genocea.com |
| Investor Relations URL | http://ir.genocea.com/index.cfm |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | May. 31, 2024 (est.) |
| Last Earnings Release | May. 05, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Genocea Biosciences Inc is a US-based biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs. Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns a pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines. |
| URL | https://www.genocea.com |
| Investor Relations URL | http://ir.genocea.com/index.cfm |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | May. 31, 2024 (est.) |
| Last Earnings Release | May. 05, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |